Consequences of treating false positive @entity6950 -induced XXXX .

@entity1 @entity882 @entity548 @entity6950 @entity750
UNASSIGNED: Identification of @entity1 with @entity6950 -induced @entity882 is encumbered by false positive enzyme-linked immuno assay (ELISA) antibody results, therefore a @entity750 release assay (SRA) is used for confirmation. Recently, several studies have demonstrated that increasing the optical density (OD) threshold (currently at 0.4) of the antibody test enhances the positive predictive value. The purpose of this study was to determine the frequency of @entity1 who were ELISA antibody positive but SRA negative, and the costs and @entity548 events associated with alternative anticoagulant treatment. We hypothesized that treating @entity1 with a positive ELISA antibody OD value of <1.0 would result in increased cost and @entity548 risk. This retrospective chart review was conducted on adult hospitalized @entity1 from 2011 to 2013. @entity1 with positive ELISA antibodies (OD of 0.4-1.0) and an SRA result were included. Eighty-five @entity1 were identified with positive antibodies (average OD of 0.66), 100  % of which were found to be SRA negative. A total of 59 @entity1 (69  %) received alternative anticoagulants. The average duration of treatment was 3.1  days, and 4 @entity1 (4.7  %) experienced a @entity548 event. The cost of testing and laboratory monitoring was  36,346 and the cost of the alternative anticoagulants totaled  47,179. The total cost was  83,525, with an average total cost per @entity1 of  982. This study adds to the body of literature suggesting treatment should only be initiated if the OD is one or greater. The high false positive rate caused increased cost and some @entity548 events.
